Maintenance treatments for opiate-dependent adolescents

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Minozzi, Silvia ^a   Amato, Laura ^a   Bellisario, Cristina ^b   Davoli, Marina ^a  

^a DEPARTMENT OF EPIDEMIOLOGY   (Italy)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; LEVACETYLMETHADOL; METHADONE; ACETYLMETHADOL; NALOXONE; NARCOTIC AGENT;

ADOLESCENT HEALTH; ALCOHOL CONSUMPTION; CANNABIS USE; DOSE RESPONSE; DRUG DETOXIFICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FOLLOW UP; HEALTH STATUS; HUMAN; MAINTENANCE THERAPY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SELF REPORT; SOCIAL STATUS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING; URINALYSIS; ADOLESCENT; MAINTENANCE CHEMOTHERAPY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PROCEDURES;

ADOLESCENT; BUPRENORPHINE; HUMANS; MAINTENANCE CHEMOTHERAPY; METHADONE; METHADYL ACETATE; NALOXONE; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942802227     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007210.pub3     Document Type: Review

References (45)

1. Lehmann WX. The use of 1-alpha-acetyl-methadol (LAAM) as compared to methadone in the maintenance and detoxification of young heroin addicts. NIDA Research Monograph 1973;8:82-3.
2. Woody GE, Poole SA, Subramanian G, Dugosh K, Bogenschutz M, Abbott P, et al.Extended vs short term buprenorphine-naloxone for treatment of opioid addicted youth: a randomized trial. JAMA 2008;300(17):2003-11. [: Erratum inJAMA. 2009 Feb 25;301(8):830.JAMA. 2013 Apr 10;309(14):1461]
3. Baer JS, Garret SB, Beadnell B, Wells EA, Peterson PL. Brief motivational intervention with homeless adolescents: evaluating effects on substance use and service utilization. Psychology of Addictive Behaviors 2007;21(4):582-6.
4. Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study. Drug and Alcohol Dependence 2010;107(2-3):253-6.
5. Ebner R, Zierer C, Schreiber W. After detoxification is before detoxification? Long term outcome of drug dependent adolescent [Nach dem Entzug = vor dem Entzug? Langzeitvrlauf bei drogenabhangigen Jugendlichen]. Psychiatrische Praxis 2007;34(Suppl 1):s42-3.
6. Fiellin DA. Treatment of adolescent opioid dependence: no quick fix. JAMA 2008;300(17):2057-9.
7. Forcehimes AA, Bogenschutz MP, Tonigan JS, Woody GE. Impact of therapeutic alliance on treatment outcome in opioid dependent adolescent and young adult treated with buprenorphine. Proceedings of the 70th Annual Scientific Meeting of the College on Problems of Drug Dependence; Puerto Rico. 2008.
8. Godley SH, Dennis ML, Godely MD, Funk RR. Thirty-months relapse trajectory cluster groups among adolescents discharged from out-patients treatment. Addiction 2004;99(Suppl 2):129-39.
9. Hill KP, Bennett HE, Griffin ML, Connery HS, Fitzmaurice GM, Subramaniam G, et al.Association of cannabis use with opioid outcomes among opioid-dependent youth. Drug and Alcohol Dependence 2013;132(1-2):342-5.
10. Hulse GK, Ngo HTT, Tait RJ. Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone. Biological Psychiatry 2010;68(3):296-302.
11. Kemp R, Harris A, Vurel E, Siharthan T. Stop using stuff: trial of a drug and alcohol intervention for young people with comorbid mental illness and drug and alcohol problems. Australasian Psychiatry 2007;15(6):490-3.
12. Lloyd RA, Katon RN, DuPont RL. Evolution of a treatment approach for young heroin addicts. Comparison of three treatment modalities. International Journal of Addiction 1974;9(2):229-39.
13. Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, et al.Comparison of pharmacological treatments for opioid-dependent adolescents. Archives of General Psychiatry 2005;62:1157-64.
14. March L, Moore SK, Solhkhah R, Badger GJ. Predictors of outcome in buprenorphine treatment for opioid-dependent youth. Proceedings of the 71st Annual Scientific Meeting of the College on Problems of Drug Dependence; 2009 June 20-25; Reno/Sparks, Nevada, USA. 2009.
15. Marsch LA, Moore S, Solhkhah R. A randomized, controlled trial of buprenorphine dosing regimens for opioid dependent youth. Proceedings of the 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence; 2011 June 18-23, Hollywood, Florida. 2011.
16. Moore SK, Guarino H, Marsch LA. "This is not who I want to be:" experiences of opioid-dependent youth before, and during, combined buprenorphine and behavioral treatment. Substance Use and Misuse 2014;49(3):303-14.
17. Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction 2010;105(9):1616-24.
18. Reimer J, Verthein U, Karow A, Schafer I, Naber D, Haasen C. Physical and mental health in severe opioid-dependent patients within a randomized controlled maintenance treatment trial. Addiction 2011;106(9):1647-55.
19. Subramaniam GA, Warden D, Minhajuddin A, Fishman MJ, Stitzer ML, Adinoff B, et al.Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. Journal of the American Academy of Child and Adolescent Psychiatry 2011;50(11):1120-8.
20. Warden D, Subramaniam GA, Carmody T, Woody GE, Minhajuddin A, Poole SA, et al.Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Adaptive Behavior 2012;37(9):1046-53.
21. Weiss L, Petry NM. Older methadone patients achieve greater durations of cocaine abstinence with contingency management than younger patients. American Journal on Addictions 2013;22(2):119-26.
22. Wilcox CE, Bogenschutz MP, Nakazawa M, Woody G. Concordance between self-report and urine drug screen data in adolescent opioid dependent clinical trial participants. Addictive Behaviors 2013;38(10):2568-74.
23. Australian Institute of Health and Welfare. Drugs in Australia 2010: tobacco, alcohol and other drugs. Drug statistics series no. 27. Cat. no. PHE 154. Canberra: AIHW. Drug Statistics Series No.18. Cat. no. PHE 80. Canberra: AIHW. Available at: http://www.aihw.gov.au/ 2011.
24. Altobelli E, Rapacchietta L, Tiberti S, Petrocelli R, Cicioni L, di Orio F, et al.Association between drug, alcohol and tobacco use in adolescents and social-familiar factors [Associazione tra l'uso di sostanze stupefacenti, alcol e tabacco negli adolescenti e contesto socio-familiare]. Annali d'Igiene 2005;17:57-65.
25. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews 2011, Issue 10. [DOI: 10.1002/14651858.CD004147]
26. Clark N, Lintzeris N, Gijsbers A, Whelan G, Ritter A, Dunlop A. LAAM maintenance versus methadone maintenance for heroin dependence. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD002210]
27. European Monitoring Centre for Drug & Drug Addiction (EMCDDA). Annual Report: The state of the drugs problem. European Union and Norway. Office for Publications of the European Communities, Luxembourg 2012.
28. Hibell B, Guttormsson U, Ahlström S, Balakireva O, Bjarnason T, Kokkevi A, et al.The 2011 ESPAD report: substance use among students in 36 European countries, Swedish Council for Information on Alcohol and Other Drugs, Stockholm, Sweden. Available at: http://www.espad.org 2012.
29. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD002208]
30. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD003410]
31. Galanter M, Glickman L, Singer D. An overview of outpatient treatment of adolescent substance abuse. Substance Abuse 2007;28(2):51-8.
32. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Available from www.cochrane-handbook.org.
33. Hopfer CJ, Khurl E, Crowley TJ, Hooks S. Adolescent heroin use: a review of the descriptive and treatment literature. Journal of Substance Abuse Treatment 2002;23(3):231-7.
34. Hunt RD, Capper L, O'Connell P. Clonidine in child and adolescent psychiatry. Journal of Child and Adolescent Psychopharmacology 1990;1:87-102.
35. Kaminer Y. Pharmacotherapy for adolescents with psychoactive substance use disorders. NIDA Research Monograph 1995;156:291-324.
36. Kellogg S, Melia D, Khuri E, Lin A, Ho A, Kreek MJ. Adolescent and young adult heroin patients: drug use and success in methadone maintenance treatment. Journal of Addictive Diseases 2006;25:15-25.
37. Levy S, Vaughan BL, Angulo M, Knight JR. Buprenorphine replacement therapy for adolescents with opioid dependence: early experience from a children’s hospital-based outpatient treatment program. Journal of Adolescent Health 2007;40:477-82.
38. Lobmaier PP, Kornør H, Kunøe N, Bjørndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD004330]
39. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD002209]
40. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD002207]
41. Mayet S, Farrell M, Ferri M, Amato L, Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD004330]
42. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD001333]
43. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the future. National survey results on drug use 1975-2012: 2012 overview. Key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan. Available at http://monitoringthefuture.org 2013.
44. Substance Abuse and Mental Health Services Administration, Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration 2013.
45. Smith B, Fagan J, Kernan k. Outcomes of heroin dependent adolescents presenting for opiate substitution treatment. Journal of Substance Abuse Treatment 2012;42:35-44.